KYVERNA THERAPEUTICS INC (KYTX) Stock Price & Overview
NASDAQ:KYTX • US5019761049
Current stock price
The current stock price of KYTX is 7.8 USD. Today KYTX is down by -2.86%. In the past month the price decreased by -4.99%. In the past year, price increased by 290%.
KYTX Key Statistics
- Market Cap
- 445.614M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.73
- Dividend Yield
- N/A
KYTX Stock Performance
KYTX Stock Chart
KYTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KYTX. While KYTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
KYTX Earnings
KYTX Forecast & Estimates
12 analysts have analysed KYTX and the average price target is 28.76 USD. This implies a price increase of 268.77% is expected in the next year compared to the current price of 7.8.
KYTX Groups
Sector & Classification
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.73. The EPS increased by 87.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.02% | ||
| ROE | -105.95% | ||
| Debt/Equity | 0 |
KYTX Ownership
KYTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 370.255B | ||
| AMGN | AMGEN INC | 15.28 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.43 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
IPO: 2024-02-08
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 129
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What does KYTX do?
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
What is the stock price of KYVERNA THERAPEUTICS INC today?
The current stock price of KYTX is 7.8 USD. The price decreased by -2.86% in the last trading session.
What is the dividend status of KYVERNA THERAPEUTICS INC?
KYTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of KYTX stock?
KYTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of KYVERNA THERAPEUTICS INC (KYTX)?
KYVERNA THERAPEUTICS INC (KYTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.73).
Would investing in KYVERNA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KYTX.
When does KYVERNA THERAPEUTICS INC (KYTX) report earnings?
KYVERNA THERAPEUTICS INC (KYTX) will report earnings on 2026-04-01, after the market close.